20:00 , Jul 13, 2018 |  BC Week In Review  |  Company News

Novartis returns rights for Aveo's preclinical cachexia program

Novartis AG (NYSE:NVS; SIX:NOVN) will return to Aveo Pharmaceuticals Inc. (NASDAQ:AVEO) rights for AV-380 and other related growth differentiation factor 15 (GDF15) inhibitor antibodies, according to an SEC filing. Aveo granted Novartis exclusive, worldwide rights to...
20:12 , Jul 3, 2018 |  BC Extra  |  Company News

Novartis returns rights for Aveo's preclinical cachexia program

Novartis AG (SIX:NOVN; NYSE:NVS) will return to Aveo Pharmaceuticals Inc. (NASDAQ:AVEO) rights for AV-380 and other related growth differentiation factor 15 (GDF15) inhibitor antibodies, according to an SEC filing. Aveo granted Novartis exclusive, worldwide rights to...
19:21 , Oct 18, 2017 |  BC Extra  |  Preclinical News

Amgen team describes GDF15's role in obesity

In a paper published Wednesday in Science Translational Medicine, researchers from Amgen Inc. (NASDAQ:AMGN) showed the involvement of growth differentiation factor 15 (GDF15) in regulating body weight in mice, rats, and non-human primates. Amgen is the...
20:42 , Oct 10, 2017 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Pancreatic cancer Patient sample, cell culture and mouse studies suggest inhibiting GDF15 could help treat pancreatic ductal adenocarcinoma (PDAC). In patients, plasma and tumor levels of GDF15 were higher than in samples from healthy volunteers,...
19:43 , Oct 3, 2017 |  BC Innovations  |  Distillery Therapeutics

Endocrine / Metabolic

INDICATION: Obesity; cachexia Mouse and rat studies suggest GDF15 could help treat obesity, and inhibiting its receptor GFRAL could help treat cachexia. In a mouse model of high-fat diet-induced obesity and a genetic rat model of...
23:12 , Oct 2, 2017 |  BC Extra  |  Preclinical News

NGM targeting GFRAL for both obesity and cachexia

NGM Biopharmaceuticals Inc. (South San Francisco, Calif.) plans to develop separate candidates modulating GDNF family receptor alpha like (GFRAL) to treat both obesity and cachexia. In a newly published paper, an NGM team showed GFRAL...
19:58 , Sep 21, 2017 |  BC Innovations  |  Targets & Mechanisms

Appetite for GFRAL

Simultaneous publications from Eli Lilly and Co., Johnson & Johnson and Novo Nordisk A/S identifying GFRAL as the receptor of the anti-obesity hormone GDF15 will undoubtedly accelerate therapeutic translation of the pathway. The race is...
17:33 , Aug 28, 2017 |  BC Extra  |  Preclinical News

Teams identify GFRAL as target for obesity

In three separate papers published in Nature Medicine on Monday, researchers at Novo Nordisk A/S (CSE:NOVOB; NYSE:NVO), Eli Lilly and Co. (NYSE:LLY) and the Janssen Research & Development LLC unit of Johnson & Johnson (NYSE:JNJ)...
07:00 , Aug 24, 2015 |  BC Week In Review  |  Company News

Aveo Pharmaceuticals, Novartis deal

Aveo granted Novartis exclusive, worldwide rights to develop and commercialize AV-380 and related antibodies targeting growth differentiation factor 15 (GDF15). Novartis also has a 90-day option to acquire Aveo’s inventory of AV-380 for...
01:01 , Aug 18, 2015 |  BC Extra  |  Company News

Aveo gains on Novartis licensing deal

Aveo Pharmaceuticals Inc. (NASDAQ:AVEO) rose $0.53 (45%) to $1.70 after it granted Novartis AG (NYSE:NVS; SIX: NOVN) an exclusive, worldwide license to preclinical candidate AV-380, in development to treat cachexia. Novartis paid $15 million up...